Skip to content

Prediction of PEP Based on the Appearance of the Major Duodenal Papilla

Prediction of Post-Endoscopic Retrograde Cholangio-Pancreatography Pancreatitis Based on the Appearance of the Major Duodenal Papilla: a Prospective, Observational, Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05800626
Acronym
PredERCP
Enrollment
1740
Registered
2023-04-05
Start date
2023-04-01
Completion date
2025-12-31
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-ERCP Acute Pancreatitis

Brief summary

This observational, prospective study aims at evaluating how the occurrence of post-Endoscopic Retrograde CholangioPancreatography (ERCP) acute pancreatitis (PEP) could be influenced by difficult biliary cannulation that might be previously assessed by the morphological appearance of native major papilla in all the patients undergoing ERCP. The rate of successful biliary cannulation across papilla types could be used as intraprocedural quality and competence metrics during training. Moreover, recognizing difficult papillae could allow reserving those to experts to decrease the odds of failed cannulation.

Interventions

ERCP performed for clinical practice

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Patients with native duodenal papilla; * Any indication to ERCP +/- biliary sphincterotomy of duodenal major papilla; * Patients able to provide a written informed consent

Exclusion criteria

* ERCP performed for disorders unrelated to biliary tract; * Previous upper gastrointestinal tract surgery; * Presence of a duodenal stricture (either malignant or benign); * Presence of a malignant infiltration of the papilla; * Concomitant anticoagulant and/or P2Y12 inhibitors therapy (clopidogrel, prasugrel, ticagrelor) that precludes the treatment; * INR \> 1.5; * Platelets count \< 80000/mm3; * Unwillingness to sign written informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Rate of PEP occurrencewithin 48 hours after the procedureRate of PEP occurrence distributed between the different native major duodenal papilla types

Secondary

MeasureTime frameDescription
Rate of difficult biliary cannulationduring the procedureRate of difficult biliary cannulation (\> 5 cannulation attempts and/or \> 5 minutes attempting to cannulate biliary duct and/or at least one passage in the pancreatic duct) distributed between the different native major duodenal papilla types
Rate of intraoperative complicationsduring the procedureRate of intraoperative complications distributed between the different native major duodenal papilla types
Rate of postoperative complications except for PEPwithin 48 hours after the procedureRate of postoperative complications except for PEP (up to 48 hours after ERCP) distributed between the different native major duodenal papilla types
Difference in the rate of difficult biliary cannulationduring the procedureDifference in the rate of difficult biliary cannulation between ERCP experts (\>300 performed procedures) and fellows (\<300 performed procedures)
occurrence of intra- and post-procedural complicationswithin 48 hours after the procedureTo evaluate the occurrence of intra- and post-procedural complications but PEP, fluoroscopic morphology of the papillary segment of distal bile duct, perioperative and intraoperative risk factors

Countries

Italy

Contacts

Primary ContactIvo Boskoski
ivo.boskoski@policlinicogemelli.it+390630156580

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026